Relapse and Emergent Resistance With Novel Short-Course Regimens for Multidrug-Resistant Tuberculosis, United States, 2022–2024

These patients highlight consequences, both for the individual and public health, of relapse and treatment failure in real-life operational settings that may not be readily evident in well-controlled and well-resourced clinical trials. Despite the advent of shorter and better tolerated bedaquiline-based regimens, US clinicians continue to face challenges in managing drug-resistant TB. These data support the need for expert management of these patients beyond routine TB care, as well as the need for close monitoring and follow-up months after treatment completion.

Authors

Institutions

Publication Details

Journal
Open Forum Infectious Diseases
Published
2025-12-26
DOI
https://doi.org/10.1093/ofid/ofaf786
Primary Topic
Tuberculosis Research and Epidemiology
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Relapse and Emergent Resistance With Novel Short-Course Regimens for Multidrug-Resistant Tuberculosis, United States, 2022–2024

Patrick Valois, Connie A. Haley, Richard Brostrom, Alfred Lardizabal et al.
Open Forum Infectious Diseases
Tuberculosis Research and Epidemiology
article

Relapse and Emergent Resistance With Novel Short-Course Regimens for Multidrug-Resistant Tuberculosis, United States, 2022–2024

Patrick Valois, Connie A. Haley, Richard Brostrom, Alfred Lardizabal, Caitlin Reed, Charles A. Peloquin, Atanaska Marinova‐Petkova, Michelle Haas, Lisa Chen, Sarah M. Labuda, Jacob Wilson, Nicole Parrish, AMEE S PATRAWALLA, James C. M. Brust, Gregory P. Bisson, Jason Cummins, Rina Liang, Susan M Ray, Vincent Escuyer, Angel Colon-Semidey, Alice Cuenca, Chima Mbakwem, David Ashkin, Katherine Arn, Barbara Cahill, Marcos C Schechter, Neela D Goswami
article en

Abstract

These patients highlight consequences, both for the individual and public health, of relapse and treatment failure in real-life operational settings that may not be readily evident in well-controlled and well-resourced clinical trials. Despite the advent of shorter and better tolerated bedaquiline-based regimens, US clinicians continue to face challenges in managing drug-resistant TB. These data support the need for expert management of these patients beyond routine TB care, as well as the need for close monitoring and follow-up months after treatment completion.

Open Forum Infectious DiseasesVol. 13(1)
Rutgers, The State University of New Jersey (US), Centers for Disease Control and Prevention (US), New York State Department of Health (US), Albert Einstein College of Medicine (US), Southeastern University (US), Mayo Clinic (US), Florida Department of Health (US), Wadsworth Center (US), Johns Hopkins University (US), Emory University (US), American Association of Colleges of Pharmacy (US), Johns Hopkins Medicine (US), Puerto Rico Department of Health (PR), International Tuberculosis Research Center (KR), Department of Public Health and Social Services (GU), Utah Department of Health (US), Mayo Clinic in Arizona (US), Tennessee Department of Health (US), Georgia Department of Public Health (US), Philadelphia Department of Public Health (US), Florida College (US)
Good health and well-being
Openalex Percentile: Top 28%
Tuberculosis Research and Epidemiology
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.